Add to ORKGThe two main reasons for a future cost increase in the pharmaceutical sector in Austria are the demographic development and medical progress.In order to contain cost increases the policy purses two objectives: Introduction of a new price formation procedure and increased generic consumption to 20% of all prescribed drugs by 2006
Authorisation of health insurance funds to collect socially adjusted user fees with simultaneous abo...
Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with hig...
The cost of the development of a new pharmaceutical product from its conception and synthesis throug...
The two main reasons for a future cost increase in the pharmaceutical sector in Austria are the demo...
There are ongoing efforts to contain cost growth in the pharmaceutical sector. This article aims to ...
There are ongoing efforts to contain cost growth in the pharmaceutical sector. This article aims to ...
European policy makers have been struggling to fulfil the partially conflicting policy goals of (1) ...
To enhance planning, control and financing competence the Austrian government is promoting the creat...
The Austrian government is promoting the creation of health purchasing agencies on state and federal...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
Health care financing has become a topic on the political agenda in Western Europe in recent decades...
Authorisation of health insurance funds to collect socially adjusted user fees with simultaneous abo...
Authorisation of health insurance funds to collect socially adjusted user fees with simultaneous abo...
Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with hig...
The cost of the development of a new pharmaceutical product from its conception and synthesis throug...
The two main reasons for a future cost increase in the pharmaceutical sector in Austria are the demo...
There are ongoing efforts to contain cost growth in the pharmaceutical sector. This article aims to ...
There are ongoing efforts to contain cost growth in the pharmaceutical sector. This article aims to ...
European policy makers have been struggling to fulfil the partially conflicting policy goals of (1) ...
To enhance planning, control and financing competence the Austrian government is promoting the creat...
The Austrian government is promoting the creation of health purchasing agencies on state and federal...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
The pharmaceutical policy environment is dynamic as new medicines are being developed and different ...
Health care financing has become a topic on the political agenda in Western Europe in recent decades...
Authorisation of health insurance funds to collect socially adjusted user fees with simultaneous abo...
Authorisation of health insurance funds to collect socially adjusted user fees with simultaneous abo...
Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with hig...
The cost of the development of a new pharmaceutical product from its conception and synthesis throug...